Equity
€87,725 ▼ 17.2%
DrSC paid out €104,000 in dividends. That is 121% of the 2025 profit.
DrSC
Lifetime
7 annual accounts with figures on one time axispeak €116,059 (2025)
€116,059▲ 6.3%
peak €85,765 (2025)
€85,765▲ 5.6%
peak €119,172 (2021)
€87,725▼ 17.2%
€112,148▲ 179%
Board1 name since 2018
1 director
Documentsfilings and deeds
30-03-2026123 days before the deadline
2025micro format
Dividend €104,000Equity from €105,960 to €87,725Debts from €40,169 to €112,148Cash from €56,038 to €89,559
Key points
from the 2025 annual accountsTurnover
≈ €210,000 estimated
The micro format states no turnover.
Debts
€112,148 ▲ 179%
Debts rose by €71,979 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.
Liquidity
1.66 was 3.27 in 2024
Short-term debts rose from €40,169 to €112,148.
Filings
7 annual accounts 1 late
The 2019 accounts came 28 days late. The other six were filed on time.
Starting capital
€18,600 100 shares
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as DrSC has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for DrSC. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0716795752
Reappointment: (statutory director)
General meeting of 26-10-2021 · Gazette deed
First establishment
Felix Timmermanslaan 2, Aartselaar
Incorporation
Founding capital of €18,600, 100 shares, €12,400 paid up · Founder: · Appointment: (statutory manager) · published on 27-12-2018 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DrSC Aartselaar | €199,873 | €116,059 | 43.9% | - |
| DR NATHALIE THEUNISSEN Kasterlee | €200,181 | €126,873 | 54.6% | - |
| Dr. Lynn Hopchet Edegem | €203,296 | €110,871 | 81.3% | - |
| LIVADE Oud-Turnhout | €171,189 | €118,769 | 10.9% | - |
| DR. SUSAN van der SPEK Antwerp | €199,774 | €122,825 | 49.7% | - |
| Dr. Klaas Vervisch Puurs-Sint-Amands | €188,333 | €128,552 | 63.7% | - |
| CABINET MEDICAL BIZJAK AXELLE Sambreville | €201,018 | €118,497 | 59.3% | - |
These companies have the same main activity as DrSC: general medical practice (NACE 86210). They are comparable in size and age: total assets between €171,000 and €203,000, founded between 2019 and 2020.
Official details
Source: KBO- Status
- Active since 21-12-2018Normal situation
- Activity
- General medical practiceNACE 86210
- Establishment unit
- 2.283.997.5332630 Aartselaar, since 01-01-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 21-03-2025
Annual accounts 2025
- €199,873▲ 36.8%
- Filing
- Filed on 30-03-2026, 123 days before the end of the filing period
Insights on DrSC
DrSC files the micro format. That format states no turnover. The gross margin rose from €44,610 in 2019 to €116,059 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DrSC
- What is the company number of DrSC?
- The company number of DrSC is 0716.795.752. The VAT number is the same number with BE in front: BE 0716.795.752.
- Where is DrSC based?
- The registered office is at Felix Timmermanslaan 2, 2630 Aartselaar.Company details
- What does DrSC do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of DrSC?
- DrSC is a private limited company (BV).
- When was DrSC founded?
- DrSC was founded on 21-12-2018.
- Is DrSC still active?
- Yes, DrSC is an active enterprise in the KBO register.
- What is the turnover of DrSC?
- The turnover in financial year 2025 is ≈ €210,000. This figure is estimated from the gross margin of €116,059 and 30 comparable companies (NACE 86210). It probably lies between €170,000 and €260,000.Financials
- Is DrSC profitable?
- In financial year 2025, DrSC made a profit of €85,765.
- Where can I find the annual accounts of DrSC?
- DrSC filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DrSC due?
- DrSC must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.